Google ScholarScopusUCL IrisORCiD

Book chapters 6
Journal articles 76
Total citations 6962
h-index 35
i10-index 52

Last updated January 2019

Book chapters

  1. Biofluid Biomarkers for Huntington’s Disease
    F Rodrigues, L Byrne & E Wild
    In Methods in Molecular Biology: Huntington’s Disease
    eds. Precious, Rosser & Dunnett. Springer, 2018.
  2. Premanifest and Early Huntington’s Disease
    E Wild & S Tabrizi.
    In Huntington’s Disease (Oxford Monographs on Medical Genetics), 3rd ed. Eds G Bates, L Jones & S Tabrizi. Oxford University Press, 2015.
  3. Huntington’s Disease & Other Choreas
    S Haider, E Wild & S Tabrizi.
    In Neurodegeneration, ed. A Schapira. Wiley, 2014.
  4. Huntington’s disease look-alike syndromes
    E Wild & S Tabrizi.
    In Oxford Textbooks in Clinical Neurology: Movement Disorders (2nd edition), ed. D Burn. Oxford University Press, 2013.
  5. Huntington’s Disease
    S Tabrizi & E Wild
    In Neurogenetics: A Guide for Clinicians (2nd edition), ed. N Wood. Cambridge University Press, 2012
  6. Huntington’s Disease and Dementia
    E Wild, N Hobbs & S Henley.
    In Neuroimaging in Dementia (1st edition), ed. F Barkhof, J Valk & N Fox. Springer-Verlag, 2011

PhD Thesis

Identification and evaluation of biomarkers for Huntington’s disease, 2009. University College London.

Peer-reviewed journal articles

  1. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease.
    Byrne LM1, Rodrigues FB2, Johnson EB2, Wijeratne PA3, De Vita E4,5, Alexander DC3,6, Palermo G7, Czech C7, Schobel S7, Scahill RI2, Heslegrave A8, Zetterberg H8,9,10,11, Wild EJ1.

    Sci Transl Med. 2018 Sep 12;10(458).

  2. Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series.
    Koriath C1, Kenny J1, Adamson G1, Druyeh R1, Taylor W1, Beck J1, Quinn L1, Mok TH1, Dimitriadis A1, Norsworthy P1, Bass N2, Carter J2, Walker Z2,3, Kipps C4, Coulthard E5, Polke JM6, Bernal-Quiros M6, Denning N7, Thomas R7, Raybould R7, Williams J7, Mummery CJ8, Wild EJ9, Houlden H6, Tabrizi SJ9, Rossor MN8, Hummerich H1, Warren JD8, Rowe JB10,11, Rohrer JD8, Schott JM8, Fox NC8, Collinge J1, Mead S12.

    Mol Psychiatry. 2018 Oct 2.

  3. Physician perception versus true efficacy of tetrabenazine for Huntington’s disease.
    Rodrigues FB1,2,3, Ferreira JJ2,3,4, Wild EJ1.

    Curr Med Res Opin. 2018 Sep;34(9):1537-1538.

  4. Perinatal insults and neurodevelopmental disorders may impact Huntington’s disease age of diagnosis.
    Barkhuizen M1, Rodrigues FB2, Anderson DG3, Winkens B4; REGISTRY Investigators of the European Huntington’s Disease Network, Wild EJ5, Kramer BW6, Gavilanes AWD7.

    Parkinsonism Relat Disord. 2018 Oct;55:55-60.

  5. Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease.
    Byrne LM1, Rodrigues FB1, Johnson EB1, De Vita E1, Blennow K2,3, Scahill R1, Zetterberg H1,2,3,4, Heslegrave A1, Wild EJ5.

    Sci Rep. 2018 Mar 9;8(1):4260.

  6. Neurofilament light protein in blood predicts regional atrophy in Huntington disease.
    Johnson EB1, Byrne LM1, Gregory S1, Rodrigues FB1, Blennow K1, Durr A1, Leavitt BR1, Roos RA1, Zetterberg H1, Tabrizi SJ1, Scahill RI1, Wild EJ2; TRACK-HD Study Group.

    Neurology. 2018 Feb 20;90(8):e717-e723.

  7. Huntington’s Disease Clinical Trials Corner: February 2018
    Rodrigues FB1,2,3, Wild EJ2.

    J Huntingtons Dis. 2018;7(1):89-98.

  8. Quantification of huntingtin protein species in Huntington’s disease patient leukocytes using optimised electrochemiluminescence immunoassays.
    Hensman Moss DJ1, Robertson N1, Farmer R2, Scahill RI1, Haider S1, Tessari MA3, Flynn G4, Fischer DF4, Wild EJ1, Macdonald D5, Tabrizi SJ1.

    PLoS One. 2017 Dec 22;12(12):e0189891.

  9. Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”.
    Rodrigues FB1,2,3, Duarte GS2,3, Costa J2,3,4,5, Ferreira JJ2,3, Wild EJ1.

    J Clin Mov Disord. 2017 Nov 22;4:19.

  10. Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay.
    Fodale V1,2, Boggio R2, Daldin M1, Cariulo C1, Spiezia MC1, Byrne LM3, Leavitt BR4, Wild EJ3, Macdonald D5, Weiss A2, Bresciani A1.

    J Huntingtons Dis. 2017;6(4):349-361.

  11. Therapies targeting DNA and RNA in Huntington’s disease.
    Wild EJ1, Tabrizi SJ2.

    Lancet Neurol. 2017 Oct;16(10):837-847.

  12. Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice.
    Soylu-Kucharz R1, Sandelius Å2, Sjögren M3, Blennow K2,4, Wild EJ5, Zetterberg H2,4,5,6, Björkqvist M3.

    Sci Rep. 2017 Oct 26;7(1):14114.

  13. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis.
    Byrne LM1, Rodrigues FB1, Blennow K2, Durr A3, Leavitt BR4, Roos RAC5, Scahill RI1, Tabrizi SJ1, Zetterberg H6, Langbehn D7, Wild EJ8.

    Lancet Neurol. 2017 Aug;16(8):601-609.

  14. Clinical Trials Corner: September 2017.
    Rodrigues FB1,2,3, Wild EJ1.

    J Huntingtons Dis. 2017;6(3):255-263.

  15. Tetrabenazine Versus Deutetrabenazine for Huntington’s Disease: Twins or Distant Cousins?
    Rodrigues FB1,2,3, Duarte GS2,3, Costa J2,3,4,5, Ferreira JJ2,3, Wild EJ1.

    Mov Disord Clin Pract. 2017 Jul-Aug;4(4):582-585.

  16. Ghost Pills: A Case Report.
    Salanio DM1, Taylor R1, Stanton JED1, Wild EJ1.

    Ann Intern Med. 2017 Apr 18;166(8):609.

  17. Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease.
    Rodrigues FB1, Byrne LM1, McColgan P1, Robertson N1, Tabrizi SJ1, Zetterberg H2,3, Wild EJ1.

    PLoS One. 2016 Sep 22;11(9):e0163479.

  18. George Huntington: a legacy of inquiry, empathy and hope.
    Wexler A1, Wild EJ2, Tabrizi SJ2.

    Brain. 2016 Aug;139(Pt 8):2326-33.

  19. Huntington’s Disease: The Most Curable Incurable Brain Disorder?
    Wild EJ1.

    EBioMedicine. 2016 Jun;8:3-4.

  20. Clinical manifestations of intermediate allele carriers in Huntington disease.
    Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C; European HD Network.

    Neurology. 2016 Aug 9;87(6):571-8.

  21. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington’s disease.
    Rodrigues FB1, Byrne L1, McColgan P1, Robertson N1, Tabrizi SJ1, Leavitt BR2, Zetterberg H3,4, Wild EJ5.

    J Neurochem. 2016 Oct;139(1):22-5.

  22. Psychogenic non-epileptic seizures in early Huntington’s disease.
    Rodrigues FB1, Wild EJ1.

    Pract Neurol. 2016 Dec;16(6):452-454.

  23. Cerebrospinal Fluid Biomarkers for Huntington’s Disease.
    Byrne LM, Wild EJ.

    J Huntingtons Dis. 2016;5(1):1-13.

  24. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients.
    Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JR, Zetterberg H, Leavitt BR, Kuhn R, Tabrizi SJ, Macdonald D, Weiss A.

    J Clin Invest. 2015 May;125(5):1979-86.

  25. Huntington disease.
    Bates GP1, Dorsey R2, Gusella JF3, Hayden MR4, Kay C4, Leavitt BR4, Nance M5, Ross CA6, Scahill RI7, Wetzel R8, Wild EJ7, Tabrizi SJ7.

    Nat Rev Dis Primers. 2015 Apr 23;1:15005.

  26. Targets for future clinical trials in Huntington’s disease: what’s in the pipeline?
    Wild EJ1, Tabrizi SJ.

    Mov Disord. 2014 Sep 15;29(11):1434-45.

  27. Neuropsychiatry and White Matter Microstructure in Huntington’s Disease.
    Gregory S1,2, Scahill RI3, Seunarine KK4, Stopford C5,6, Zhang H7, Zhang J7, Orth M8, Durr A9, Roos RA10, Langbehn DR11,12, Long JD11,12, Johnson H13, Rees G1,2, Tabrizi SJ3,14, Craufurd D5,6; Track-HD Investigators.

    J Huntingtons Dis. 2015;4(3):239-49.

  28. Huntington disease: natural history, biomarkers and prospects for therapeutics.
    Ross CA1, Aylward EH2, Wild EJ3, Langbehn DR4, Long JD4, Warner JH5, Scahill RI3, Leavitt BR6, Stout JC7, Paulsen JS4, Reilmann R8, Unschuld PG9, Wexler A10, Margolis RL1, Tabrizi SJ3.

    Nat Rev Neurol. 2014 Apr;10(4):204-16.

  29. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies.
    Hensman Moss DJ1, Poulter M, Beck J, Hehir J, Polke JM, Campbell T, Adamson G, Mudanohwo E, McColgan P, Haworth A, Wild EJ, Sweeney MG, Houlden H, Mead S, Tabrizi SJ.

    Neurology. 2014 Jan 28;82(4):292-9.

  30. Suicidal ideation in a European Huntington’s disease population.
    Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ; REGISTRY investigators of the European Huntington’s Disease Network.

    J Affect Disord. 2013 Oct;151(1):248-58.

  31. The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients.
    Metzger S, Walter C, Riess O, Roos RA, Nielsen JE, Craufurd D; REGISTRY Investigators of the European Huntington’s Disease Network, Nguyen HP.

    PLoS One. 2013 Jul 22;8(7):e68951.

  32. JAK/STAT Signalling in Huntington’s Disease Immune Cells.
    Träger U1, Magnusson A2, Lahiri Swales N3, Wild E4, North J3, Lowdell M3, Björkqvist M2.

    PLoS Curr. 2013 Dec 13;5.

  33. β-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington’s Disease.
    Vittori A1, Orth M2, Roos RA3, Outeiro TF4, Giorgini F5, Hollox EJ5; REGISTRY investigators of the European Huntington’s Disease Network.

    J Huntingtons Dis. 2013 Mar 27;2(1):107-124.

  34. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ1, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR; TRACK-HD Investigators.

    Lancet Neurol. 2013 Jul;12(7):637-49.

  35. Corpus callosal atrophy in premanifest and early Huntington’s disease.
    Crawford HE1, Hobbs NZ1, Keogh R2, Langbehn DR3, Frost C2, Johnson H4, Landwehrmeyer B5, Reilmann R6, Craufurd D7, Stout JC8, Durr A9, Leavitt BR10, Roos RA11, Tabrizi SJ1, Scahill RI1; TRACK-HD Investigators.

    J Huntingtons Dis. 2013;2(4):517-26.

  36. Biomarkers for Huntington’s disease: an update.
    Scahill RI1, Wild EJ, Tabrizi SJ.

    Expert Opin Med Diagn. 2012 Sep;6(5):371-5.

  37. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study.
    Hobbs NZ1, Barnes J, Frost C, Henley SM, Wild EJ, Macdonald K, Barker RA, Scahill RI, Fox NC, Tabrizi SJ.

    AJNR Am J Neuroradiol. 2010 Jun;31(6):1036-41.

  38. Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression.
    Weiss A1, Träger U, Wild EJ, Grueninger S, Farmer R, Landles C, Scahill RI, Lahiri N, Haider S, Macdonald D, Frost C, Bates GP, Bilbe G, Kuhn R, Andre R, Tabrizi SJ.

    J Clin Invest. 2012 Oct;122(10):3731-6.

  39. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington’s disease.
    Stout JC1, Jones R, Labuschagne I, O’Regan AM, Say MJ, Dumas EM, Queller S, Justo D, Santos RD, Coleman A, Hart EP, Dürr A, Leavitt BR, Roos RA, Langbehn DR, Tabrizi SJ, Frost C.

    J Neurol Neurosurg Psychiatry. 2012 Jul;83(7):687-94.

  40. Huntington’s disease: fighting on many fronts.
    Andre R, Wild EJ, Tabrizi SJ.

    Brain. 2012 Apr;135(Pt 4):998-1001.

  41. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.
    Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS; PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB; REGISTRY study of the European Huntington’s Disease Network, Myers RH; HD-MAPS Study Group, MacDonald ME, Gusella JF; COHORT study of the HSG.

    Neurology. 2012 Mar 6;78(10):690-5.

  42. Discrepancies in reporting the CAG repeat lengths for Huntington’s disease.
    Quarrell OW, Handley O, O’Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB; European Huntington’s Disease Network.

    Eur J Hum Genet. 2012 Jan;20(1):20-6.

  43. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ1, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR; TRACK-HD investigators.

    Lancet Neurol. 2012 Jan;11(1):42-53.

  44. Observing Huntington’s disease: the European Huntington’s Disease Network’s REGISTRY.
    Orth M; European Huntington’s Disease Network, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB.

    J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1409-12.

  45. HDBuzz: empowering patients through accessible education.
    Wild EJ1, Carroll JB.

    Trends Mol Med. 2012 Jan;18(1):1-3.

  46. Pitfalls in the use of voxel-based morphometry as a biomarker: examples from huntington disease.
    Henley SM1, Ridgway GR, Scahill RI, Klöppel S, Tabrizi SJ, Fox NC, Kassubek J; EHDN Imaging Working Group.

    AJNR Am J Neuroradiol. 2010 Apr;31(4):711-9.

  47. Brain-derived neurotrophic factor in patients with Huntington’s disease.
    Zuccato C1, Marullo M, Vitali B, Tarditi A, Mariotti C, Valenza M, Lahiri N, Wild EJ, Sassone J, Ciammola A, Bachoud-Lèvi AC, Tabrizi SJ, Di Donato S, Cattaneo E.

    PLoS One. 2011;6(8):e22966.

  48. NMDA receptor gene variations as modifiers in Huntington disease: a replication study.
    Saft C, Epplen JT, Wieczorek S, Landwehrmeyer GB, Roos RA, de Yebenes JG, Dose M, Tabrizi SJ, Craufurd D; REGISTRY Investigators of the European Huntington’s Disease Network, Arning L.

    PLoS Curr. 2011 Oct 4;3:RRN1247.

  49. Abnormal peripheral chemokine profile in Huntington’s disease.
    Wild E1, Magnusson A, Lahiri N, Krus U, Orth M, Tabrizi SJ, Björkqvist M.

    PLoS Curr. 2011 Apr 13;3:RRN1231.

  50. Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease.
    Munsie L1, Caron N, Atwal RS, Marsden I, Wild EJ, Bamburg JR, Tabrizi SJ, Truant R.

    Hum Mol Genet. 2011 May 15;20(10):1937-51.

  51. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis.
    Tabrizi SJ1, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC; TRACK-HD Investigators.

    Lancet Neurol. 2011 Jan;10(1):31-42.

  52. Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY.
    Orth M1, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB; Investigators of the European Huntington’s Disease Network.

    Version 2. PLoS Curr. 2010 Sep 28 [revised 2011 Apr 13];2:RRN1184.

  53. Rate and acceleration of whole-brain atrophy in premanifest and early Huntington’s disease.
    Wild EJ1, Henley SM, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ.

    Mov Disord. 2010 May 15;25(7):888-95.

  54. The progression of regional atrophy in premanifest and early Huntington’s disease: a longitudinal voxel-based morphometry study.
    Hobbs NZ1, Henley SM, Ridgway GR, Wild EJ, Barker RA, Scahill RI, Barnes J, Fox NC, Tabrizi SJ.

    J Neurol Neurosurg Psychiatry. 2010 Jul;81(7):756-63.

  55. Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease.
    Aziz NA1, Jurgens CK, Landwehrmeyer GB; EHDN Registry Study Group, van Roon-Mom WM, van Ommen GJ, Stijnen T, Roos RA.

    Neurology. 2009 Oct 20;73(16):1280-5.

  56. Serial volumetric MRI in Parkinsonian disorders.
    Wild EJ1, Fox NC.

    Mov Disord. 2009;24 Suppl 2:S691-8.

  57. Harnessing immune alterations in neurodegenerative diseases.
    Björkqvist M1, Wild EJ, Tabrizi SJ.

    Neuron. 2009 Oct 15;64(1):21-4.

  58. Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington’s disease.
    Hobbs NZ1, Henley SM, Wild EJ, Leung KK, Frost C, Barker RA, Scahill RI, Barnes J, Tabrizi SJ, Fox NC.

    Neuroimage. 2009 Oct 1;47(4):1659-65.

  59. Relationship between CAG repeat length and brain volume in premanifest and early Huntington’s disease.
    Henley SM1, Wild EJ, Hobbs NZ, Scahill RI, Ridgway GR, Macmanus DG, Barker RA, Fox NC, Tabrizi SJ.

    J Neurol. 2009 Feb;256(2):203-12.

  60. Whole-brain atrophy as a measure of progression in premanifest and early Huntington’s disease.
    Henley SM1, Wild EJ, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ.

    Mov Disord. 2009 Apr 30;24(6):932-6.

  61. Immune markers for Huntington’s disease?
    Wild E, Björkqvist M, Tabrizi SJ.

    Expert Rev Neurother. 2008 Dec;8(12):1779-81.

  62. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington’s disease.
    Leoni V1, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, Henley SM, Hobbs NZ, Mandelli ML, Grisoli M, Björkhem I, Cattaneo E, Di Donato S.

    Brain. 2008 Nov;131(Pt 11):2851-9.

  63. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease.
    Björkqvist M1, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, Möller T, Tabrizi SJ.

    J Exp Med. 2008 Aug 4;205(8):1869-77.

  64. Rapid eye movement sleep disturbances in Huntington disease.
    Arnulf I1, Nielsen J, Lohmann E, Schiefer J, Wild E, Jennum P, Konofal E, Walker M, Oudiette D, Tabrizi S, Durr A.

    Arch Neurol. 2008 Apr;65(4):482-8.

  65. Defective emotion recognition in early HD is neuropsychologically and anatomically generic.
    Henley SM1, Wild EJ, Hobbs NZ, Warren JD, Frost C, Scahill RI, Ridgway GR, MacManus DG, Barker RA, Fox NC, Tabrizi SJ.

    Neuropsychologia. 2008;46(8):2152-60.

  66. Huntington’s disease phenocopies are clinically and genetically heterogeneous.
    Wild EJ1, Mudanohwo EE, Sweeney MG, Schneider SA, Beck J, Bhatia KP, Rossor MN, Davis MB, Tabrizi SJ.

    Mov Disord. 2008 Apr 15;23(5):716-20.

  67. Biomarkers for Huntington’s disease.
    Wild EJ1, Tabrizi SJ.

    Expert Opin Med Diagn. 2008 Jan;2(1):47-62.

  68. Vasculitic presentation of staphylococcal meningitis.
    Bentley P1, Qadri F, Wild EJ, Hirsch NP, Howard RS.

    Arch Neurol. 2007 Dec;64(12):1788-9.

  69. The differential diagnosis of chorea.
    Wild EJ1, Tabrizi SJ.

    Pract Neurol. 2007 Nov;7(6):360-73.

  70. Huntington’s disease phenocopy syndromes.
    Wild EJ1, Tabrizi SJ.

    Curr Opin Neurol. 2007 Dec;20(6):681-7.

  71. Analysis of potential transcriptomic biomarkers for Huntington’s disease in peripheral blood.
    Runne H1, Kuhn A, Wild EJ, Pratyaksha W, Kristiansen M, Isaacs JD, Régulier E, Delorenzi M, Tabrizi SJ, Luthi-Carter R.

    Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14424-9.

  72. Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates.
    Dalrymple A1, Wild EJ, Joubert R, Sathasivam K, Björkqvist M, Petersén A, Jackson GS, Isaacs JD, Kristiansen M, Bates GP, Leavitt BR, Keir G, Ward M, Tabrizi SJ.

    J Proteome Res. 2007 Jul;6(7):2833-40.

  73. Plasma neurofilament heavy chain levels in Huntington’s disease.
    Wild EJ1, Petzold A, Keir G, Tabrizi SJ.

    Neurosci Lett. 2007 May 7;417(3):231-3.

  74. Predict-HD and the future of therapeutic trials.
    Wild EJ, Tabrizi SJ.

    Lancet Neurol. 2006 Sep;5(9):724-5.

  75. Deja vu in neurology.
    Wild E1.

    J Neurol. 2005 Jan;252(1):1-7.

  76. Thyrotoxic periodic paralysis in a Maori patient.
    Wild E1.

    N Z Med J. 2004 Dec 17;117(1207):U1204.

  77. Uterine diverticulum as a late complication of caesarean section.
    Wild E1, Gull S.

    J Obstet Gynaecol. 2003 Jan;23(1):88.